P16INK4a: A central player in cellular senescence and a promising aging biomarker in elderly cancer patients

Journal of Geriatric Oncology

Volumn 2, Issue 4, 2011, Pages 259-269

  Vandenberk, Bert ^a   Brouwers, Barbara ^a   Hatse, Sigrid ^a   Wildiers, Hans ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Aging biomarker; Cancer; Cellular senescence; Elderly; P16INK4a

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RETINOBLASTOMA PROTEIN;

AGING; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CHROMOSOME 4; CHROMOSOME 9P; CHROMOSOME 9P21; DNA DAMAGE; GENE; HUMAN; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; P16INK4A GENE; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SENESCENCE; T LYMPHOCYTE; TELOMERE; TELOMERE UNCAPPING;

EID: 80054926719     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2011.08.004     Document Type: Review

References (85)

1. Pal S.K., Katheria V., Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 2010, 60(2):120-132.
2. Maccormick R.E. Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty?. Med Hypotheses 2006, 67(2):212-215.
3. Collins C.J., Sedivy J.M. Involvement of the INK4a/Arf gene locus in senescence. Aging Cell 2003, 2(3):145-150.
4. Sharpless N.E. Ink4a/Arf links senescence and aging. Exp Gerontol 2004, 39(11-12):1751-1759.
5. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264(5157):436-440.
6. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995, 83(6):993-1000.
7. Collins I., Garrett M.D. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 2005, 5(4):366-373.
8. Cánepa E.T., Scassa M.E., Ceruti J.M., Marazita M.C., Carcagno A.L., Sirkin P.F., et al. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 2007, 59(7):419-426.
9. Massagué J. G1 cell-cycle control and cancer. Nature 2004, 432(7015):298-306.
10. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13(12):1501-1512.
11. Harbour J.W., Luo R.X., Dei Santi A., Postigo A.A., Dean D.C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999, 98(6):859-869.
12. Matheu A., Maraver A., Serrano M. The Arf/p53 pathway in cancer and aging. Cancer Res 2008, 68(15):6031-6034.
13. Toledo F., Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006, 6(12):909-923.
14. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
15. Ben-Porath I., Weinberg R.A. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005, 37(5):961-976.
16. Sharpless N.E. The persistence of senescence. Sci Aging Knowledge Environ 2003, (33):PE24. 2003.
17. Te Poele R.H., Okorokov A.L., Jardine L., Cummings J., Joel S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002, 62(6):1876-1883.
18. Robles S.J., Adami G.R. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 1998, 16(9):1113-1123.
19. Brookes S., Rowe J., Gutierrez Del Arroyo A., Bond J., Peters G. Contribution of p16(INK4a) to replicative senescence of human fibroblasts. Exp Cell Res 2004, 298(2):549-559.
20. Jacobs J.J., de Lange T. p16INK4a as a second effector of the telomere damage pathway. Cell Cycle 2005, 4(10):1364-1368.
21. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426(6963):194-198.
22. Smogorzewska A., de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J 2002, 21(16):4338-4348.
23. Ohtani N., Yamakoshi K., Takahashi A., Hara E. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest 2004, 51(3-4):146-153.
24. Chen Q., Fischer A., Reagan J.D., Yan L.J., Ames B.N. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci U S A 1995, 92(10):4337-4341.
25. Blander G., de Oliveira R.M., Conboy C.M., Haigis M., Guarente L. Superoxide dismutase 1 knock-down induces senescence in human fibroblasts. J Biol Chem 2003, 278(40):38966-38969. Epub 2003 Jul 18.
26. Forman H.J., Maiorino M., Ursini F. Signaling functions of reactive oxygen species. Biochemistry 2010, 49(5):835-842.
27. Sitte N., Merker K., Von Zglinicki T., Grune T., Davies K.J. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part I-Effects of proliferative senescence. FASEB J 2000, 14(15):2495-2502.
28. Itahana K., Zou Y., Itahana Y., Martinez J.L., Beausejour C., Jacobs J.J., et al. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 2003, 23(1):389-401.
29. Iwasa H., Han J., Ishikawa F. Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway. Genes Cells 2003, 8(2):131-144.
30. Wahl G.M., Carr A.M. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 2001, 3(12):E277-E286.
31. Brookes S., Rowe J., Ruas M., Llanos S., Clark P.A., Lomax M., et al. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 2002, 21(12):2936-2945.
32. Benanti J.A., Galloway D.A. Normal human fibroblasts are resistant to RAS-induced senescence. Mol Cell Biol 2004, 24(7):2842-2852.
33. Iwasa H., Han J., Ishikawa F. Mitogen-activated protein kinase p38 defines the common senescence-signaling pathway. Genes Cells 2003, 8(2):131-144.
34. Maldonado J.L., Timmerman L., Fridlyand J., Bastian B.C. Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am J Pathol 2004, 164(5):1783-1787.
35. Matheu A., Pantoja C., Efeyan A., Criado L.M., Martin-Caballero J., Flores J.M., et al. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev 2004, 18:2736-2746.
36. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Ingelmann H., et al. P53 mutant mice that display early ageing-associated phenotypes. Nature 2002, 415(6867):45-53.
37. Ruas M., Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998, 1378(2):F115-F177.
38. Kahlem P., Dörken B., Schmitt C.A. Cellular senescence in cancer treatment: friend or foe?. J Clin Invest 2004, 113(2):169-174.
39. Lodygin D., Menssen A., Hermeking H. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest 2002, 110(11):1717-1727.
40. Hunter M., Wang Y., Eubank T., Baran C., Nana-Sinkam P., Marsh C. Survival of monocytes and macrophages and their role in health and disease. Front Biosci 2009, 14:4079-4102.
41. Coppé J.P., Patil C.K., Rodier F., Sun Y., Muñoz D.P., Goldstein J., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008, 6(12):2853-2868.
42. Waldman T., Zhang Y., Dillehay L., Yu J., Kinzler K., Vogelstein B., et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997, 3:1034-1036.
43. Krtolica A., Parrinello S., Lockett S., Desprez P.Y., Campisi Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A 2001, 98(21):12072-12077.
44. Beauséjour C.M., Krtolica A., Galimi F., Narita M., Lowe S.W., Yaswen P., et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003, 22(16):4212-4222.
45. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109(3):335-346.
46. Jeyapalan J.C., Sedivy J.M. Cellular senescence and organismal aging. Mech Ageing Dev 2008, 129(7-8):467-474.
47. Collado M., Blasco M.A., Serrano M. Cellular senescence in cancer and aging. Cell 2007, 130(2):223-233.
48. Summers K.E., Goff L.K., Wilson A.G., Gupta R.K., Lister T.A., Fitzgibbon J. Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol 2001, 19(2):420-424.
49. Bose S., Deininger M., Gora-Tybor J., Goldman J.M., Melo J.V. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998, 92:3362-3367.
50. Hornsby P.J. Senescence as an anticancer mechanism. J Clin Oncol 2007, 25(14):1852-1857.
51. Pawelec G., Larbi A., Derhovanessian E. Senescence of the human immune system. J Comp Pathol 2010, 142(Suppl 1):S39-S44.
52. Pawlec G., Derhovanessian E., Larbi A. Immunosenescence and cancer. Crit Rev Oncol Hematol 2010, 75(2):165-172.
53. Derhovanessian E., Solana R., Larbi A., Pawelex G. Immunity, ageing and cancer. Immune Ageing 2008, 5:11.
54. Van Heemst D., den Reijer P.M., Westendorp R.G. Ageing or cancer: a review on the role of caretakers and gatekeepers. Eur J Cancer 2007, 43(15):2144-2152.
55. Shea J., Agarwala V., Philippakis A.A., Maguire J., Banks E., DePristo M., et al. Comparing strategies to fine-map the association of common SNPs at chromosome 9p21 with type 2 diabetes and myocardial infarction. Nat Genet 2011, 43(8):801-805.
56. Burd C.E., Jeck W.R., Liu Y., Sanoff H.K., Wang Z., Sharpless N.E. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PloS Genet 2010, 6(12):e1001233.
57. Harismendy O., Notani D., Song X., Rahim N.G., Tanasa B., Heintzman N., et al. 9p21 DNA variants associated with coronary artery disease impair interferon-γ signaling response. Nature 2011, 470(7333):264-268.
58. Liu Y., Sanoff H.K., Cho H., Burd C.E., Torrice C., Ibrahim J.G., et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell 2009, 8(4):439-448.
59. Song Z., von Figura G., Liu Y., Kraus J.M., Torrice C., Dillon P., et al. Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell 2010, 9(4):607-615.
60. Tsygankov D., Liu Y., Sanoff H.K., Sharpless N.E., Elston T.C. A quantitative model for age-dependent expression of the p16INK4a tumor suppressor. Proc Natl Acad Sci U S A 2009, 106(39):16562-16567.
61. Resler S., Bartkova J., Niederegger H., Bartek J., Scharffetter-Kochanek K., jansen-Dürr P., et al. p16INK4a is a robust in vivo biomarker of cellular aging in human skin. Aging Cell 2006, 5(5):379-389.
62. Kim R.H., Lee R.S., Williams D., Bae S., Woo J., Lieberman M., et al. Bisphosphonates induce senescence in normal human oral keratinocytes. J Dent Res 2011, 90(6):810-816.
63. Butler R.N., Sprott R., Warner H., Bland J., Feuers R., Forster M., et al. Biomarkers of aging: from primitive organisms to humans. J Gerontol A Biol Sci Med Sci 2004, 59(6):B560-B567.
64. Karasik D., Demissie S., Cupples L.A., Kiel D.P. Disentangling the genetic determinants of human aging: biological age as an alternative to the use of survival measures. J Gerontol A Biol Sci Med Sci 2005, 60(5):574-587.
65. Cawthon R.M., Smith K.R., O'Brien E., Sivatchenko A., Kerber R.A. Association between telomere length in blood and mortality in people aged 60years or older. Lancet 2003, 361(9355):393-395.
66. Benetos A., Okuda K., Lajemi M., Kimura M., Thomas F., Skurnick J., et al. Telomere length as an indicator of biological aging-the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001, 37(2 Part 2):381-385.
67. Epel E.S., Merkin S.S., Cawthon R., Blackburn E.H., Adler N.E., Pletcher M.J., et al. The rate of leukocyte telomere shortening predicts mortality from cardiovascular disease in elderly men. Aging (Albany NY) 2008, 1(1):81-88.
68. Valdes A.M., Deary I.J., Gardner J., Kimura M., Lu X., Spector T.D., et al. Leukocyte telomere length is associated with cognitive performance in healthy women. Neuobiol Aging 2010, 31(6):986-992.
69. Savale L., Chaouat A., Bastuji-Garin S., Marcos E., Boyer L., Maitre B., et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 179(7):566-571.
70. Houben J.M., Mercken E.M., Ketelslegers H.B., Bast A., Wouters E.F., Hageman G.J., et al. Telomere shortening in chronic obstructive pulmonary disease. Respir Med 2009, 103(2):230-236. Fev.
71. Terry D.F., Nolan V.G., Andersen S.I., Perls T.T., Cawthon R. Association of longer telomeres with better health in centenarians. J Gerontol A Biol Sci Med Sci 2008, 63(8):809-812.
72. Martin-Ruiz C.M., Gussekloo J., van Heemst D., von Zglinicki T., Westendorp R.G. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell 2005, 4(6):287-290.
73. Harris S.E., Dcary I.J., MacIntyre A., Lamb K.J., Radhakrishnan K., Starr J.M., et al. The association between telomere length, physical health, cognitive ageing, and mortality in non-demented older people. Neurosci Lett 2006, 406(3):260-264.
74. Njajou O.T., Hsueh W.-C., Blackburn E.H., Newman A.B., Wu S.H., Li R., et al. Association between telomere length, specific causes of death, and years of healthy life in health, aging, and body composition, a population-based cohort study. J Gerontol A Biol Sci Med Sci 2009, 64(8):860-864.
75. Chebel A., Bauwens S., Gerland L.-M., Belleville A., Urbanowicz I., Roborel de Climens A., et al. Telomere uncapping during in vitro T-lymphocyte senescence. Aging Cell 2009, 8(1):52-64.
76. Vasto S., Carruba G., Lio D., Colonna-Romano G., Di Bona D., Candore G., et al. Inflammation, ageing and cancer. Mech Ageing Dev 2009, 130(1-2):40-45.
77. Yao X., Li H., Leng S.X. Inflammation and immune system alterations in frailty. Clin Geriatr Med 2011, 27(1):79-87.
78. Swardfager W., Lanctôt K., Rothenburg L., Wong A., Cappell J., Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010, 68(10):930-941.
79. Danesh J., Kaptoge S., Mann A.G., Sarwar N., Wood A., Angleman S.B., et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008, 5(4):e78.
80. Bertoni A.G., Burke G.L., Owusu J.A., Carnethon M.R., Vaidya D., Barr R.G., et al. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010, 33(4):804-810.
81. O'Donovan A., Pantell M.S., Puterman E., Dhabhar F.S., Blackburn E.H., Yaffe K., et al. Cumulative inflammatory load is associated with short leukocyte telomere length in the health, aging and body composition study. PLoS One 2011, 6(5):e19687. Epub 2011 May 13.
82. Jiang H., Schiffer E., Zhangfa S., Wang J., Zürbig P., Thedieck K., et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. PNAS 2008, 105(32):11299-11304.
83. von Figura G., Hartmann D., Song Z., Rudolph K.L. Role of telomere dysfunction in aging and its detection by biomarkers. J Mol Med (Berl) 2009, 87(12):1165-1171.
84. Zürbig P., Decramer S., Dakna M., Jantos J., Good D.M., Coon J.J., et al. The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics 2009, 9(8):2108-2117.
85. Stolzing A., Jones E., McGonagle D., Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008, 129(3):163-173.